UroGen Pharma Ltd. Annual Net Income (Loss) Attributable to Parent in USD from 2015 to 2023

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
UroGen Pharma Ltd. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from 2015 to 2023.
  • UroGen Pharma Ltd. Net Income (Loss) Attributable to Parent for the quarter ending June 30, 2024 was -$33.4M, a 38.4% decline year-over-year.
  • UroGen Pharma Ltd. Net Income (Loss) Attributable to Parent for the twelve months ending June 30, 2024 was -$114M, a 4.16% decline year-over-year.
  • UroGen Pharma Ltd. annual Net Income (Loss) Attributable to Parent for 2023 was -$102M, a 6.87% increase from 2022.
  • UroGen Pharma Ltd. annual Net Income (Loss) Attributable to Parent for 2022 was -$110M, a 0.94% increase from 2021.
  • UroGen Pharma Ltd. annual Net Income (Loss) Attributable to Parent for 2021 was -$111M, a 13.7% increase from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 -$102M +$7.54M +6.87% Jan 1, 2023 Dec 31, 2023 10-K 2024-03-14
2022 -$110M +$1.04M +0.94% Jan 1, 2022 Dec 31, 2022 10-K 2024-03-14
2021 -$111M +$17.7M +13.7% Jan 1, 2021 Dec 31, 2021 10-K 2023-03-24
2020 -$128M -$23.3M -22.2% Jan 1, 2020 Dec 31, 2020 10-K 2022-03-21
2019 -$105M -$29.5M -39% Jan 1, 2019 Dec 31, 2019 10-K 2021-03-18
2018 -$75.7M -$55.7M -278% Jan 1, 2018 Dec 31, 2018 10-K 2020-03-02
2017 -$20M -$18.1M -930% Jan 1, 2017 Dec 31, 2017 10-K 2020-03-02
2016 -$1.94M +$10.7M +84.7% Jan 1, 2016 Dec 31, 2016 10-K 2019-02-28
2015 -$12.7M Jan 1, 2015 Dec 31, 2015 20-F 2018-03-15
* An asterisk sign (*) next to the value indicates that the value is likely invalid.